Frequently Asked Questions

The DAC (Drug Affinity Complex) is a chemical modification that enables covalent binding to albumin, extending the half-life to 6-8 days. Without DAC, the half-life is approximately 30 minutes. Without DAC produces acute GH pulses; with DAC produces sustained GH elevation.

It is a modified version of Growth Hormone-Releasing Factor (GRF) amino acids 1-29, which contain the full biological activity of the 44-amino-acid GHRH. The modifications (4 amino acid substitutions) improve resistance to enzymatic degradation.

CJC-1295 activates the GHRH receptor while ipamorelin activates the ghrelin receptor. These are complementary pathways, and research shows co-stimulation produces GH release that is synergistic (greater than the sum of individual effects).

CJC-1295 without DAC, also known as Modified GRF(1-29), is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH) with four amino acid substitutions designed to improve metabolic stability. The modifications (Ala at position 2 to D-Ala, Asn at position 8 to Gln, Ala at position 15 to Ala (retained), and Met at position 27 to Leu) confer resistance to DPP-4 and other proteolytic enzymes while preserving full GHRH receptor binding affinity.

CJC-1295 no DAC has been investigated across 4 primary research areas: Growth Hormone Release, GHRH Receptor, Body Composition, Anti-Aging. Each area has published preclinical data supporting the peptide's activity through distinct but sometimes overlapping molecular pathways.

Teichman et al. (2006) showed CJC-1295 produced sustained dose-dependent increases in GH and IGF-1 levels following single subcutaneous injections in healthy adults. Additionally, ionescu & Bhisitkul (2000) reviewed the development of GHRH analogues with enhanced stability, establishing the structure-activity relationships that guided CJC-1295 design.

Clinical research used single doses of 15-60 mcg/kg subcutaneously. Research combination protocols with ipamorelin typically study both components simultaneously.

Store lyophilized powder at -20C. Reconstituted solution should be refrigerated at 2-8C and used within 21 days. Moderately stable in solution.

The CAS registry number for CJC-1295 no DAC is 863288-34-0. The molecular weight is 3367.97 g/mol. The amino acid sequence is: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Ar....

Key publications include: Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Among others, there are 3 peer-reviewed publications cited in our research profile, all indexed in PubMed.

Research-grade CJC-1295 no DAC should be at minimum 98% purity as verified by HPLC analysis. Mass spectrometry should confirm molecular identity. Always request a batch-specific Certificate of Analysis (COA) from an independent third-party laboratory before using any peptide in experiments.

Add bacteriostatic water slowly down the inside wall of the vial — never spray directly onto the lyophilized powder. Gently swirl until fully dissolved; the solution should be clear and colorless. Calculate your desired concentration based on the peptide mass and volume of solvent added. Use a sterile syringe and swab the vial stopper with alcohol before each withdrawal.

No. CJC-1295 no DAC is designated Research Use Only (RUO). It is not approved by the FDA for human consumption, veterinary use, or any therapeutic purpose. All references to research findings on this site describe preclinical laboratory studies, not clinical recommendations. Consult a licensed healthcare provider for any medical questions.

CJC-1295 no DAC and CJC-1295 DAC act through different molecular mechanisms and are studied for overlapping but distinct research applications. Researchers often use both compounds in parallel to compare pathway-specific effects. Detailed mechanism comparisons are available in our research section.

Once reconstituted, CJC-1295 no DAC should be stored at 2-8°C (standard refrigerator temperature) and used within 30 days. Lyophilized (unreconstituted) peptide is stable for 12-24 months at -20°C when kept sealed and protected from light. Never refreeze a reconstituted solution, and avoid repeated freeze-thaw cycles.

Research-grade CJC-1295 no DAC with 98%+ purity, HPLC verification, and third-party COAs is available at researchvials.com. All peptides ship from the USA with cold-chain packaging to maintain product integrity. This site is an educational resource and does not sell products directly.

DAC stands for Drug Affinity Complex. It is a maleimidopropionic acid modification that forms a covalent bond with serum albumin after injection, extending the peptide's half-life from ~30 minutes to 6-8 days.

It depends on the research goal. The DAC version provides sustained GH/IGF-1 elevation suitable for chronic studies. The non-DAC version produces acute GH pulses closer to natural physiology, preferred for studies of pulsatile GH secretion.

CJC-1295 with DAC is the albumin-conjugating version of CJC-1295, featuring a Drug Affinity Complex (DAC) — a reactive maleimidopropionic acid group that forms a covalent bond with serum albumin after subcutaneous injection. This albumin conjugation dramatically extends the circulating half-life from approximately 30 minutes (without DAC) to 6-8 days, enabling sustained elevation of GH and IGF-1 from a single administration.

CJC-1295 DAC has been investigated across 4 primary research areas: Growth Hormone Release, Sustained GHRH Agonism, Body Composition, IGF-1 Research. Each area has published preclinical data supporting the peptide's activity through distinct but sometimes overlapping molecular pathways.

Teichman et al. (2006) showed a single CJC-1295 DAC injection produced sustained GH elevation for up to 6 days and IGF-1 elevation for 9-11 days in healthy adults. Additionally, alba et al. (2006) demonstrated CJC-1295 DAC normalized growth in GHRH knockout mice, confirming its biological activity through the GHRH receptor.

Clinical studies used single subcutaneous doses of 30-60 mcg/kg. Due to the long half-life, dosing frequency in research is typically once weekly.

Store lyophilized powder at -20C. Reconstituted solution should be refrigerated at 2-8C and used within 21 days. The DAC modification is stable in lyophilized form.

The CAS registry number for CJC-1295 DAC is 863288-34-0. The molecular weight is ~3647.28 g/mol. The amino acid sequence is: Modified GRF(1-29) with maleimidopropionic acid-DAC conjugate.

Key publications include: Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Among others, there are 2 peer-reviewed publications cited in our research profile, all indexed in PubMed.

Research-grade CJC-1295 DAC should be at minimum 98% purity as verified by HPLC analysis. Mass spectrometry should confirm molecular identity. Always request a batch-specific Certificate of Analysis (COA) from an independent third-party laboratory before using any peptide in experiments.

Add bacteriostatic water slowly down the inside wall of the vial — never spray directly onto the lyophilized powder. Gently swirl until fully dissolved; the solution should be clear and colorless. Calculate your desired concentration based on the peptide mass and volume of solvent added. Use a sterile syringe and swab the vial stopper with alcohol before each withdrawal.

No. CJC-1295 DAC is designated Research Use Only (RUO). It is not approved by the FDA for human consumption, veterinary use, or any therapeutic purpose. All references to research findings on this site describe preclinical laboratory studies, not clinical recommendations. Consult a licensed healthcare provider for any medical questions.

CJC-1295 DAC and CJC-1295 no DAC act through different molecular mechanisms and are studied for overlapping but distinct research applications. Researchers often use both compounds in parallel to compare pathway-specific effects. Detailed mechanism comparisons are available in our research section.

Once reconstituted, CJC-1295 DAC should be stored at 2-8°C (standard refrigerator temperature) and used within 30 days. Lyophilized (unreconstituted) peptide is stable for 12-24 months at -20°C when kept sealed and protected from light. Never refreeze a reconstituted solution, and avoid repeated freeze-thaw cycles.

Research-grade CJC-1295 DAC with 98%+ purity, HPLC verification, and third-party COAs is available at researchvials.com. All peptides ship from the USA with cold-chain packaging to maintain product integrity. This site is an educational resource and does not sell products directly.

Research peptides are short chains of amino acids — typically between 2 and 50 residues — synthesized for laboratory investigation. They let researchers study receptor binding kinetics, cellular signaling cascades, and enzyme interactions with high specificity. They are not intended for human use.

It means HPLC analysis confirmed that at least 98% of the lyophilized powder is your target peptide. The remaining fraction is typically truncated sequences or deletion peptides from synthesis. This matters because impurities can activate off-target pathways and wreck dose-response curves. Mass spectrometry provides the second check, confirming molecular identity.

Keep lyophilized (freeze-dried) vials at -20°C. They are remarkably stable in this form — 12 to 24 months with no significant degradation. Once you reconstitute with bacteriostatic water, move to 2-8°C and use within 30 days. The cardinal rules: no repeated freeze-thaw cycles, protect from light, sterile technique every time you draw from the vial.

It means a lab with zero financial ties to the manufacturer independently verifies identity, purity, and endotoxin levels. This eliminates the obvious conflict of interest in self-testing. The resulting Certificate of Analysis (COA) gives you hard data about what is actually in the vial — not what someone claims is in it.

Swab the vial stopper with an alcohol wipe. Draw your bacteriostatic water into a sterile syringe. Inject slowly down the inside glass wall of the vial — not directly onto the cake of powder, which can denature it. Let it sit for a minute, then gently swirl. Never shake. The solution should be perfectly clear. If it is cloudy, something went wrong.

It means the product exists solely for laboratory research — in vitro cell culture work, preclinical animal studies, and educational purposes. RUO compounds have not gone through FDA approval for human safety or efficacy. They cannot legally be sold as drugs, supplements, food additives, or for veterinary use.

Look for four things. First, HPLC purity — should be 98%+ with a clean chromatogram showing one dominant peak. Second, mass spectrometry — the observed molecular weight should match the theoretical weight within instrument precision. Third, appearance — should state white or off-white lyophilized powder. Fourth, endotoxin testing — should be below detection limits for injectable-grade material.

PubMed (pubmed.ncbi.nlm.nih.gov) is the gold standard. Search by peptide name, CAS number, or mechanism. Start with review articles — they synthesize the field so you do not have to read 50 primary papers first. Every PMID we cite on this site links directly to the PubMed entry so you can verify our claims.

This site is purely educational — we do not sell anything. All research peptides referenced here are available at researchvials.com, with 98%+ purity, third-party COAs, and USA-based cold-chain shipping.